Last reviewed · How we verify
NCT07145294
Induced Pluripotent Stem Cells-derived Small Extracellular Vesicles May Promote Neurological Function and Improve Cognitive Impairment in Acute Ischemic Stroke Patients
Phase 1, PHASE2 trial testing iEV in Cognitive Impairment in 40 participants. Currently enrolling.
30 July 2025
Quick facts
| Lead sponsor | Hongmei Wang |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 7 March 2025 |
| Primary completion | 30 July 2025 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- iEV — full drug profile →
- Basic treatments
Conditions studied
- Cognitive Impairment — all drugs for Cognitive Impairment →
Sponsor
Hongmei Wang
Who can join
18 and older, any sex, with Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study primarily evaluates whether iEV nasal administration can improve neurological impairment and cognitive dysfunction in patients with acute cerebral infarction and cognitive impairment, and preliminarily explores its clinical efficacy.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Extracellular vesicles: Revolutionizing targeted therapy for ischemic stroke.
Bai J, Yang J, Liu W, Han B, et al · · 2026 · PMID 42180524 · DOI 10.1016/j.apsb.2026.03.025 -
The role of natural and engineered exosomes in repairing damage to the nervous system.
Liu T, Fan Y, Zhang Q, Yang L, et al · · 2026 · PMID 41808084 · DOI 10.1186/s12951-026-04268-7
Verify or expand the search:
- PubMed search for NCT07145294
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of iEV
Trials testing the same drug.
- NCT07111325 — Safety and Preliminary Efficacy of iEVs Injection in Treating Lateral Epicondylitis of Humerus · Phase 1, PHASE2 · recruiting
Other recruiting trials for Cognitive Impairment
Currently open trials in the same condition.
- NCT07504276 — Tele-Rehabilitation vs Conventional Rehabilitation for Cognitive Improvement in Stroke Survivors. · NA · recruiting
- NCT07396779 — Cognitive Task-Based Walking Effects on Cognition, Mood, Sleep, and Quality of Life in Older Adults With Brain Fog · NA · active not recruiting
- NCT07084831 — A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment i · Phase 3 · recruiting
- NCT07125378 — Living Independence Through Functional Training · Phase 1, PHASE2 · recruiting
- NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07145294 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hongmei Wang
- Last refreshed: 28 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07145294.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing